Download the free whitepaper: Unravelling the complexities of genomics-driven drug discovery

Genomics-driven drug discovery holds immense promise in developing targeted therapies by leveraging genetic and biomarker information to understand the root causes of diseases. However, the field faces significant hurdles.

In this whitepaper, we examine the obstacles of limited recontactability, scarcity of multi-omics data sets, lack of diversity in data, and the challenge of scaling research for rare diseases. By addressing these challenges and proposing strategies to address them, this whitepaper aims to chart a path by which we can harness the full potential of genomics-driven drug discovery.

 

whitepaper image
download icon

Download whitepaper

The genetics signal in today's clinical trial pipeline

Sano analyzed 4,565 actively recruiting clinical trials across the US, UK, EU, Japan, and South Korea, classifying each one for genetic relevance, rare disease status, therapy area, treatment modality, and sponsor. The goal was to map where genetic patient identification is already shaping enrollment, and where it's headed next.

The data shows genetic involvement now reaches nearly half of all oncology trials, and that the share of trials needing genetic testing varies widely by treatment modality, from 94% of gene therapy trials down to 3% of device trials. It also surfaces which sponsors, from large pharma to specialist biotechs, carry the heaviest rare disease concentration in their active pipelines.

Download the report to see where genetic patient identification is getting harder across today's clinical trial pipeline.

Industry-1